Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...

SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...